For Oliver Rando, being in Tom Maniatis’ Harvard lab when the PI and his team worked out the role of the proteasome in NF-KB activation made the difference between a career in research and one with possibility for direct clinical impact.

Being a member of the lab during its groundbreaking work on NF-KB — the work that led to today’s use of proteasome inhibitors as the frontline treatment for multiple myeloma, Rando says — was the pivotal element in his deciding to get an MD in addition to the PhD he already had in mind.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.